je.st
news
Tag: phase
ASTM Approves Latest Revisions to Phase I Environmental Site Assessment Process Standard
2013-11-06 06:00:00| Industrial Newsroom - All News for Today
ASTM International Committee E50 on Environmental Assessment, Risk Management and Corrective Action has issued revised version of ASTM E1527, Practice for Environmental Site Assessments: Phase I Environmental Site Assessment Process. Standard describes Phase I ESA process, a tool used to conduct research to identify potential for releases of hazardous substances or petroleum products that could lead to liability to new property owners if not identified, evaluated, addressed, and properly ...This story is related to the following:Green & CleanSearch for suppliers of:
Tags: site
process
standard
latest
FIRST RF CorporationAwarded Sixteen SBIR Phase I Contracts From DoD 13.1 And 13.2 Solicitations
2013-11-05 07:30:25| rfglobalnet News Articles
FIRST RF Corporation announced today that it has been awarded sixteen Small Business Innovative Research (SBIR) Phase I contracts from the DoD 13.1 and 13.2 competitions.
Tags: phase
contracts
sixteen
dod
Babcock and SEA selected for Royal Navys phase two of SCB programme
2013-11-05 01:00:00| Naval Technology
The UK Ministry of Defence (MoD) has selected Babcock and SEA team for phase II of the vanguard replacement programme (VRP) submarine communications buoy (SCB) system's technology demonstrator programme (TDP).
Tags: selected
sea
phase
programme
Mercks Investigational 9-valent HPV Vaccine, V503, Prevented 97 Percent of Cervical, Vaginal and Vulvar Pre-cancers Caused by Five Additional HPV Types, in Phase III Study
2013-11-04 13:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Immunogenicity non-inferior to GARDASIL for original four HPV types Merck expects to file Biologics License Application with U.S. FDA in 2013 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that in the pivotal Phase III efficacy study, its investigational 9-valent HPV vaccine (V503) prevented approximately 97 percent of cervical, vaginal and vulvar pre-cancers caused by HPV types 31, 33, 45, 52, and 58. Language: English Contact: Media:Pamela Eisele, 908-423-5042orImraan Munshi, 215-652-0059orInvestor:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: in
additional
study
iii
Gilead Announces Phase 3 Results for an All-Oral, Sofosbuvir-Based...
2013-11-02 15:57:50| Biotech - Topix.net
Gilead Sciences, Inc. today announced results from a Phase 3 study, PHOTON-1, evaluating the investigational once-daily nucleotide analogue sofosbuvir for the treatment of chronic hepatitis C virus infection among patients co-infected with HIV.
Tags: results
phase
announces
gilead
Sites : [201] [202] [203] [204] [205] [206] [207] [208] [209] [210] [211] [212] [213] [214] [215] [216] [217] [218] [219] [220] next »